Table 1 Plasma MMP1 and MMP8 levels in relation to standard prognostic markers.

all patients

2.0 (0.8–3.7)

10.5 (4.4–19.1)

menopausal status

premenopausal

2.0 (0.5–4.0)

1.02 (0.91–1.13)

14.8 (5.4–20.8)

0.98 (0.95–1.00)

postmenopausal

2.0 (1.0–3.5)

10.0 (4.2–18.8)

unknown

2.2 (1.3–3.0)

6.0 (3.6–13.4)

breast cancer

inflammatory

1.1 (0.6–2.0)

0.74 (0.56–0.98)

6.3 (3.5–8.5)

0.90 (0.83–0.97)

non-inflammatory

2.2 (0.8–3.9)

11.0 (4.7–20.5)

non-inflammatory breast cancer patients

Primary tumour size

pT1

2.4 (1.1–4.2)

1.11 (1.00–1.23)

10.2 (3.8–20.5)

0.99 (0.97–1.01)

pT2

2.2 (0.8–3.7)

11.0 (4.6–18.8)

pT3

1.3 (0.6–2.2)

16.4 (6.4–24.0)

axillary lymph node status

pN0

2.3 (1.1–4.1)

1.04 (0.94–1.15)

7.5 (3.5–19.1)

0.99 (0.97–1.01)

pN1

1.9 (0.8–3.6)

13.4 (8.0–22.5)

pN2

0.9 (0.1–3.4)

18.0 (12.5–22.0)

pN3

2.7 (1.9–4.6)

5.7 (2.9–8.9)

histologic grade

well (G1)

3.4 (1.0–4.6)

0.99 (0.90–1.10)

4.9 (3.3–20.9)

1.00 (0.98–1.03)

moderatly (G2)

1.6 (0.6–3.0)

15.2 (4.8–21.6)

poorly (G3)

2.2 (1.1–4.0)

11.0 (5.4–18.9)

oestrogen receptor

Negative

1.6 (0.2–3.7)

1.13 (0.92–1.39)

8.9 (4.3–22.9)

1.00 (0.97–1.04)

Positive

2.2 (0.9–4.0)

11.3 (5.1–20.1)

progesteron receptor †

Negative

2.0 (0.2–3.5)

1.13 (0.95–1.35)

12.3 (4.9–23.5)

0.98 (0.95–1.00)

Positive

2.2 (0.9–4.0)

10.9 (4.7–19.4)

Her2 overexpression

Negative

2.2 (0.8–3.8)

0.97 (0.82–1.14)

10.9 (4.9–20.2)

1.03 (1.00–1.06)

Positive

1.8 (1.1–4.4)

13.7 (3.2–25.7)